MCM
CSTL icon

Matarin Capital Management’s Castle Biosciences CSTL Stock Holding History

Matarin Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,250
Closed -$537K – 198
2020
Q2 		$537K Buy
+14,250
New +$487K 0.11% 170

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Matarin Capital Management's CSTL Position: Q3 2020 in Review

Matarin Capital Management sold out of Castle Biosciences (CSTL) in Q3 2020, closing a stake of 14,250 shares — an estimated $537K sold.

Matarin Capital Management first reported a position in CSTL in Q2 2020 and held it in 1 quarter. The position peaked at $537K in Q2 2020. 144 funds tracked by Wall St. Rank hold CSTL as of Q3 2020.

  • Matarin Capital Management reported no remaining Castle Biosciences position as of Q3 2020 after selling out during the quarter.
  • Matarin Capital Management sold 14,250 Castle Biosciences shares in Q3 2020, an estimated $537K.
  • Matarin Capital Management first reported a position in Castle Biosciences in Q2 2020 and held it in 1 quarter.
  • Matarin Capital Management's Castle Biosciences position peaked at $537K in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2020.

Based on Matarin Capital Management's 13F filing for Q3 2020, filed 10 Dec 2020.